Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company backed by Novo, is seeking to raise as much as $212 million in a US initial public offering. The company joins a select group of biotechs tapping public markets for growth capital this year. A successful listing would provide substantial funding to advance its pipeline through expensive late-stage clinical trials.

The IPO arrives amid a cautiously recovering market for biotech offerings after a prolonged downturn. Clinical-stage companies like Hemab face substantial capital needs to fund research and development, making public markets an attractive funding avenue despite ongoing regulatory scrutiny. Novo's backing provides credibility and potential strategic support for the company's long-term development plans.

If completed, the offering would represent one of the larger biotech IPOs in recent memory, signaling renewed investor appetite for early-stage therapeutic companies. The deal's success will likely depend on broader market conditions and investor sentiment toward clinical-stage biotechs at the time of pricing.